A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Clinical trial NCT06395519 · RECRUITING

Trial details

NCT number: NCT06395519
Sponsor: 858 Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced or Metastatic Solid Tumors Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovarian Cancer BRCA2 Mutation ER+ Breast Cancer Castrate Resistant Prostate Cancer BRCA1 Mutation BRCA Mutation Endometrial Cancer Colorectal Cancer

Start date: 2024-05-13
Primary completion: 2026-12-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.